Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04783766 | Safety, Tolerability and Pharmacokinetics Study of CK-3773274 | PHASE1 | COMPLETED | 28 | — | — | Apr 10, 2021 | Aug 5, 2021 | Jan 24, 2025 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| CK-3773274 for Single Ascending Dose (SAD) Cohorts | EXPERIMENTAL | Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274 |
| Placebo comparator for SAD Cohorts | PLACEBO_COMPARATOR | Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator |
| CK-3773274 for Multiple Dose (MD) Cohort | EXPERIMENTAL | Subjects will receive multiple doses of CK-3773274 |
| Placebo comparator for MD Cohort | PLACEBO_COMPARATOR | Subjects will receive multiple doses of placebo comparator |
| Name | Type | Description |
|---|---|---|
| CK-3773274 | DRUG | CK-3773274- Tablets |
| Placebo | DRUG | Placebo- Tablets |
Inclusion Criteria: 1. Healthy Chinese males and females between 18 and 45 years of age, inclusive 2. Body weight ≥50kg and body mass index (BMI) within 18 to 26 kg/m2, inclusive 3. Acoustic windows adequate for accurate transthoracic echocardiograms 4. Normal cardiac structure and function, as det...